Histone deacetylase (HDAC) was identified as a promising therapeutic target for cancer treatment as it plays a central role in chromosome structural remodeling and gene-transcriptional regulation, with altered expression and mutation of HDAC linked to tumor development and occurrence [1]. This evidence concerns the gene HDAC9 and neoplasm.